We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Response to Comment on "Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth".
- Authors
McAnally, Heath B.; Bonnet, Udo
- Abstract
Here we would like to make it clear to them and our readership that we also urge caution - with rational and evidence-based benefit:risk stratification - in the prescription of these drugs. Conclusion "Knee-jerk" prescription of GPNs in response to a well-intentioned and warranted push toward multimodal and opioid-sparing analgesic regimens has undoubtedly opened the door for misuse, abuse, and even dependence/addiction among many high-risk individuals. We would like to thank Peckham et al. [[1]] for their critique of our review [[2]] outlining the benefits and risks of gabapentinoids (GPNs) in the context of general medical, specialty pain management, and addiction medicine practice. Keywords: Addiction; Epidemiology; Gabapentin; Gabapentinoids; Pregabalin; Risk EN Addiction Epidemiology Gabapentin Gabapentinoids Pregabalin Risk 757 762 6 05/17/21 20210601 NES 210601 Digital Features This article is published with digital features to facilitate understanding of the article.
- Subjects
MEDICAL personnel; MEDICAL practice; COMPULSIVE behavior; SUBSTANCE abuse; DRUGS
- Publication
Pain & Therapy, 2021, Vol 10, Issue 1, p757
- ISSN
2193-8237
- Publication type
Letter
- DOI
10.1007/s40122-020-00224-x